Antibody building blocks stuck together with bacterial superglue can protect against bunyaviruses, and herald a new approach to developing antibodies to fight emerging viruses.
Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in eLife.
The findings provide a new approach to preventing and treating infections of emerging viruses and could also potentially be used in therapeutics for other diseases.
Bunyaviruses are mainly carried by insects, such as mosquitoes, and can have devastating effects on animal and human health. The World Health Organization has included several of these viruses on the Blueprint list of pathogens likely to cause epidemics in humans in the face of absent or insufficient countermeasures.
“After vaccines, antiviral and antibody therapies are considered the most effective tools to fight emerging life-threatening virus infections,” explains author Paul Wichgers Schreur, a senior scientist of Wageningen Bioveterinary Research, The Netherlands. “Specific antibodies called VHHs have shown great promise in neutralising a respiratory virus of infants. We investigated if the same antibodies could be effective against emerging bunyaviruses.”
Antibodies naturally found in humans and most other animals are composed of four ‘chains’ – two heavy and two light. VHHs are the antigen-binding domains of heavy chain-only antibodies found in camelids and are fully functional as a single domain. This makes VHHs smaller and able to bind to pathogens in ways that human antibodies cannot. Furthermore, the single chain nature makes them perfect building blocks for the construction of multifunctional complexes.
In this study, the researchers immunised llamas with two prototypes of bunyaviruses, the Rift Valley fever virus (RVFV) and the Schmallenberg virus (SBV), to generate VHHs that target an important part of the virus’ infective machinery, the glycoprotein head. They found that RVFV and SBV VHHs recognised different regions within the glycoprotein structure.
When they tested whether the VHHs could neutralise the virus in a test tube, they found that single VHHs could not do the job. Combining two different VHHs had a slightly better neutralising effect against SBV, but this was not effective for RVFV. To address this, the team used ‘superglue’ derived from bacteria to stick multiple VHHs together as a single antibody complex. The resulting VHH antibody complexes efficiently neutralised both viruses, but only if the VHHs in the complex targeted more than one region of the virus glycoprotein head.
Studies in mice with the best performing VHH antibody complexes showed that these complexes were able to prevent death. The number of viruses in the blood of the treated mice was also substantially reduced compared with the untreated animals.
To work in humans optimally, antibodies need to have all the effector functions of natural human antibodies. To this end, the team constructed llama-human chimeric antibodies. Administering a promising chimeric antibody to mice before infection prevented lethal disease in 80% of the animals, and treating them with the antibody after infection prevented mortality in 60%.
“We’ve harnessed the beneficial characteristics of VHHs in combination with bacterial superglues to develop highly potent virus neutralising complexes,” concludes senior author Jeroen Kortekaas, Senior Scientist at Wageningen Bioveterinary Research, and Professor of the Laboratory of Virology, Wageningen University, The Netherlands. “Our approach could aid the development of therapeutics for bunyaviruses and other viral infections, as well as diseases including cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Harnessing antibodies as pathogen hunterson April 15, 2021 at 6:34 am
On a microscopic level, humans face an existential threat every day. All sorts of tiny pathogens, like bacteria and viruses, work constantly to get inside our bodies, reproduce, and continue their ...
- Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilitieson April 14, 2021 at 5:00 am
Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will grant Pure Biologics’ access to select synthetic antibody phage display libraries derived only from sequences ...
- Molecular Matrix and GenScript Partner to Launch SARS-CoV-2 Neutralizing Antibody Testing Service for Publicon April 13, 2021 at 6:30 am
PISCATAWAY, New Jersey and WEST SACRAMENTO, Calif., April 13, 2021 /PRNewswire/ -- Molecular Matrix, Inc. (MMI) and GenScript Biotech Corp.
- Regeneron says antibody injection drastically reduced Covid infectionon April 12, 2021 at 10:55 am
People who were exposed to Covid and received under-the-skin injections of Regeneron's synthetic antibody treatment were 81 percent less likely to develop the disease compared to those on a ...
- Regeneron says antibody injection drastically reduced Covid infectionon April 12, 2021 at 10:51 am
People who were exposed to Covid and received under-the-skin injections of Regeneron's synthetic antibody treatment were 81 percent less likely to develop the disease compared to those on a placebo, ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Virus neutralising complexes
- The dream vaccineon April 15, 2021 at 1:37 pm
In 2017, three leading vaccine researchers submitted a grant application with an ambitious goal. At the time, no one had proved a vaccine could stop even a single beta coronavirus ...
- Vaccines that can protect against many coronaviruses could prevent another pandemicon April 15, 2021 at 10:19 am
And in March, the Coalition for Epidemic Preparedness Innovations (CEPI), an international nonprofit launched in 2017, announced it would spend up to $200 million on a new program to accelerate the ...
- New Tanzanian Variant Detected In Angola From An Entirely New Branch Of SARS-CoV-2on April 15, 2021 at 9:23 am
The versatility of SARS-CoV-2 to evolve new variants that increase transmissibility, virulence, and immune evasion is a new troubling feature of the Covid-19 pandemic. The recent discovery of a novel ...
- Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Developmenton April 15, 2021 at 1:58 am
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is today hosting its second annual Vaccines Day, with presentations highlighting the ...
- Moderna CEO: Covid Booster Shot Will Be Ready By Fallon April 14, 2021 at 6:53 am
Following is the unofficial transcript of a CNBC interview with Moderna (NASDAQ:MRNA) CEO Stephane Bancel on CNBC’s “Squawk Box” today ...